$VRTX Headlines Twitter shows how companies enrich

New Post Public Reply Private Reply Replies (0) Message Board

Feb 12, 2015 at 10:57 AM

$VRTX Headlines

Twitter shows how companies enrich executives at your expense 9:50 a.m. Feb. 6, 2015 - Philip van Doorn
Vertex Pharmaceuticals shares drop 2.2% 9:33 a.m. Feb. 6, 2015 - Sue Chang
Google, Amazon earnings on tap after hours 3:40 p.m. Jan. 29, 2015 - Sue Chang
Charting the S&P 500’s slow-motion breakout 11:00 a.m. Nov. 7, 2014 - Michael Ashbaugh
Twitter gives out 47% of its revenue in stock bonuses 12:51 p.m. Oct. 29, 2014 - Philip van Doorn
11 stocks rising the most as the market heads toward a correction 10:29 a.m. Oct. 15, 2014 - Philip van Doorn
Everything you need to know about investing you learned in grade school 2:09 p.m. Oct. 7, 2014 - Tomi Kilgore
S&P, Nasdaq violate major support 9:02 a.m. Oct. 1, 2014 - Michael Ashbaugh
Bed Bath, Starz gain; Citizens Financial debuts 2:52 p.m. Sept. 24, 2014 - Sue Chang
Oracle falls on earnings, Ellison move; Alibaba soars on debut 3:08 p.m. Sept. 19, 2014 - Sue Chang
Vertex Pharmaceuticals shares jump 4.9%, pace S&P 500 advancers 8:59 a.m. Sept. 5, 2014 - Tomi Kilgore
U.S. stocks push higher; biotechs rally 3:06 p.m. Aug. 13, 2014 - Anora Mahmudova
Vertex leads S&P 500, King drops on outlook 2:55 p.m. Aug. 13, 2014 - Sue Chang
10 stocks suffering the biggest cuts in earnings estimates 12:39 p.m. Aug. 11, 2014 - Philip van Doorn
Kinder Morgan soars, Tesla rallies on upgrade 11:46 a.m. Aug. 11, 2014 - Sue Chang
Mobileye rises for second day; Michael Kors falls 12:23 p.m. Aug. 4, 2014 - Sue Chang
Charting a slow-motion breakout attempt 10:08 a.m. July 23, 2014 - Michael Ashbaugh
U.S. stocks fall; Dow in triple-digit loss 3:36 p.m. June 24, 2014 - Anora Mahmudova
Dow falls over 100 points; energy stocks sell off: Stock market live blog recap 2:46 p.m. June 24, 2014 - blogs.marketwatch.com
Vertex soars on trial success; Best Buy gets buy rating 2:30 p.m. June 24, 2014 - Sue Chang

Drug Making Breaks Away From Old Ways 8:07 p.m. Feb. 8, 2015 - The Wall Street Journal Interactive Edition
Stock Market News for February 06, 2015 - Market News 10:10 a.m. Feb. 6, 2015 - Zacks.com
5 Stocks With Awful Analyst Earnings Revisions — SOL IFT GLYC RELL VRTX 1:45 a.m. Feb. 6, 2015 - InvestorPlace.com
Arkansas Reaches Settlement in Cystic Fibrosis Drug Suit 1:49 p.m. Feb. 5, 2015 - The Wall Street Journal Interactive Edition
Insider Trading Alert - DAN, VRTX And ENSG Traded By Insiders 11:30 a.m. Feb. 5, 2015 - TheStreet.com
Biotech Stock Roundup: Biogen Impresses with 4Q Results, Gilead & AbbVie HCV Drugs in Focus - Analyst Blog 11:47 a.m. Feb. 4, 2015 - Zacks.com
Vertex Should Expect Approvals For Its Cystic Fibrosis Medications 9:16 p.m. Feb. 2, 2015 - Seeking Alpha
Obama Announces Genetic-Mapping Plan 7:48 p.m. Jan. 30, 2015 - The Wall Street Journal Interactive Edition
Vertex Pharmaceuticals (VRTX) Downgraded From Hold to Sell 4:40 p.m. Jan. 30, 2015 - TheStreet.com
Is the 'January Effect' Signaling a Down Year for the Stock Market? 3:14 p.m. Jan. 30, 2015 - TheStreet.com
IBB Is +34% For 1 Year And +7.31% For 2015 - But What Are The Risks? 10:07 a.m. Jan. 30, 2015 - Seeking Alpha
Vertex Pharmaceuticals Slumps: VRTX Falls 5.9% in Session - Tale of the Tape 8:52 a.m. Jan. 30, 2015 - Zacks.com
Vertex Pharma Verging on Full Valuation 8:19 a.m. Jan. 30, 2015 - Barrons.com
Baird Releases Comments After Vertex Earnings Call 2:08 p.m. Jan. 29, 2015 - benzinga.com
Alexion Beats Q4 Estimates, Appoints New CEO 12:28 p.m. Jan. 29, 2015 - Investors Business Daily
Vertex Pharmaceutical (VRTX) Stock Declines Today Following Earnings Realease 11:44 a.m. Jan. 29, 2015 - TheStreet.com
Maxim Downgrades Vertex Pharmaceuticals After Earnings 11:00 a.m. Jan. 29, 2015 - benzinga.com
Vertex Posts Wider 4Q Loss, Affirms Kalydeco Outlook - Analyst Blog 10:10 a.m. Jan. 29, 2015 - Zacks.com
Vertex Phamraceuticals (VRTX) Earnings Report: Q4 2014 Conference Call Transcript 9:03 a.m. Jan. 29, 2015 - TheStreet.com
Continued Expansion Into The Cystic Fibrosis Treatment Market Bodes Well For Vertex 7:52 a.m. Jan. 29, 2015 - Seeking Alpha

Vertex to Present at Upcoming Investor Conferences 4:06 p.m. Feb. 11, 2015 - BusinessWire - BZX
Today's Review on Biotech Equities - Vertex Pharma, Alexion Pharma, Arrowhead Research, Medivation, and Incyte 9:10 a.m. Feb. 10, 2015 - PR Newswire - PRF
Technical Scrutiny on Biotech Stocks - Galena Biopharma, Synta Pharma, Merrimack Pharma, Vertex Pharma, and Spectrum Pharma 8:55 a.m. Jan. 7, 2015 - PR Newswire - PRF
Vertex Announces Upcoming Presentation at the J.P. Morgan Healthcare Conference and Date of Fourth Quarter and Full Year 2014 Financial Results 4:02 p.m. Jan. 6, 2015 - BusinessWire - BZX
On Winning Track: Complementary Research on Vertex, Ignyta, Novartis, Boeing and TransCanada 9:20 a.m. Dec. 30, 2014 - PR Newswire - PRF
U.S. Food and Drug Administration Approves KALYDECO® (ivacaftor) for Use in People with Cystic Fibrosis Ages 6 and Older Who Have the R117H Mutation 3:11 p.m. Dec. 29, 2014 - BusinessWire - BZX
David Altshuler, M.D., Ph.D., Joins Vertex as Executive Vice President of Global Research and Chief Scientific Officer 9:02 a.m. Dec. 15, 2014 - BusinessWire - BZX
MassMutual Announces the Election of Three Members to its Board of Directors 12:00 p.m. Dec. 10, 2014 - PR Newswire - PRF
Technical Scrutiny on Biotech Stocks - CTI BioPharma, Vertex Pharma, Progenics Pharma, iBio, and NewLink Genetics 8:45 a.m. Dec. 2, 2014 - PR Newswire - PRF
Vertex to Present at Deutsche Bank BioFEST on December 2 4:02 p.m. Nov. 20, 2014 - BusinessWire - BZX
Cystic Fibrosis Foundation Royalty Sale Will Be Transformational for People with CF 9:03 a.m. Nov. 19, 2014 - PR Newswire - PRF
Vertex Submits Applications in the U.S. and Europe for Approval of Lumacaftor in Combination with Ivacaftor for People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation 7:03 a.m. Nov. 5, 2014 - BusinessWire - BZX
Vertex to Present at the Credit Suisse Healthcare Conference on November 11 3:04 p.m. Oct. 30, 2014 - BusinessWire - BZX
Arrival of Former FDA Senior Officials Accelerates Greenleaf Expansion 7:00 a.m. Oct. 29, 2014 - BusinessWire - BZX
Vertex Reports Third Quarter 2014 Financial Results 3:04 p.m. Oct. 28, 2014 - BusinessWire - BZX
Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 8:00 a.m. Oct. 24, 2014 - PR Newswire - PRF
FDA Advisory Committee Recommends Approval of KALYDECO® (ivacaftor) for Use in People with Cystic Fibrosis Ages 6 and Older Who Have the R117H Mutation 3:47 p.m. Oct. 21, 2014 - BusinessWire - BZX
Vertex to Announce Third Quarter 2014 Financial Results on October 28 3:01 p.m. Oct. 14, 2014 - BusinessWire - BZX
Vertex Reviews Recent Progress and Announces Upcoming Milestones in the Development of Multiple Combinations of Medicines that Target the Underlying Cause of Cystic Fibrosis 8:32 a.m. Oct. 9, 2014 - BusinessWire - BZX
Senior Housing Properties Trust Announces LEED® Gold Certification of the Vertex Pharmaceuticals Biotech Buildings 7:02 a.m. Oct. 8, 2014 - BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Boots Group Wraps Up Consent Solicitation for Notes

Consent Solicitation's Critical Role in Acquisition No time for dawdling—Boots Group's gathered up their consent cards for hefty senior secured notes, and we're talking close to a billion smackers here. It's a bold move to grease the wheels on looming acquisition maneuvers. We're looking at a €650 million and a £375 million stack of senior secured notes patiently...

Gemmy's Orchestra of Lights Op. 2 Unveils New Show

Jazzing Up the Holidays with Gemmy's Latest Innovation Just when you thought holiday displays couldn't get more extravagant, along comes Gemmy with its latest wonder—the Orchestra of Lights™ Op. 2. Exclusively hitting Lowe's shelves, this isn't your average set of twinkling bulbs. It's an all-out sensory assault, mixing tunes straight out of yuletide hit lists with...

Gildan Activewear Faces 18.8% Hit Amid Securities Suit

Gildan's Channel Stuffing Allegations If July showers bring August flowers, then what do June allegations bring? A stock nosedive, if you’re Gildan Activewear. Investors woke up June 16, 2026, to a harrowing drop, with shares slipping nearly 19%. It's the kind of gut-punch that makes one wonder if summer vacation is over before it even starts. Jehoshaphat Research...

PZZA Faces Class Action: Strategic Shake-up or Misstep?

Papa John's: Doughy Deceit or Strategic Misfire? Once in a while, a corporation trips over its own ambitious production line, and Papa John’s (NASDAQ:PZZA) is the latest contestant to make headlines for all the wrong reasons. Investors in this pizza powerhouse are being called to the courtroom as a class action lawsuit unfolds, marking a turbulent stage in the...

Denarius Metals Unveils Technical Insight for Toral Project

Denarius Metals Shares Tech Report on Toral Project It's a curious moment in the mining world when Denarius Metals decides to drop their latest gem—a technical report on the Toral Project. We're talking about a full-bodied document rooted in the stringent National Instrument 43-101 standards. This isn't some half-baked release; it's a robust assertion of where they...

Callender Bowlin's Legal Eagles Soar in Texas 2026

The Spotlight on CB Trial's Legal Titans Roll the dice, folks—who stands up in Texas’ legal playground? It's Callender Bowlin, PLLC's hotshots again securing their hallmark in the 2026 Texas Super Lawyers gauntlet. This ain’t their first rodeo, either. Founding partners Mark Callender and Josh Bowlin—names synonymous with high-stakes litigation—continue to bask...

TORRAS Stands Tall with iPhone 18 Pro Cases

By Riley Hayes Updated Oct 24, 2026 Category News Views 135

TORRAS Shines in Magnetic Stand Case Evaluation In the whirlwind of smartphone accessories, where the battle lines are drawn between protection and functionality, TORRAS has emerged victorious with its magnetic stand cases for the iPhone 18 Pro and its beefier brother, the iPhone 18 Pro Max. Expert Consumers—a trusted name in product evaluations—has given TORRAS the...

Apalutamide Boosts Outlook for Prostate Cancer Treatment

Fresh Findings on High-Risk Prostate Cancer Treatments In an industry that often feels like a game of chess, Johnson & Johnson's recent news unveils another one of their strategic moves with the announcement of breakthrough results from their Phase 3 PROTEUS substudy. Turns out, ERLEADA®, their apalutamide treatment, isn't just another pawn; it's a potential...

Leviton Ignites Bridgestone Arena's Modern Makeover

A Power Play in Technology: Leviton's Big Move Forget your lazy Sunday strolls, the latest buzz is all about connectivity at sports arenas. Leviton, the century-old stalwart in networking and electrical solutions, has just tied the knot with the Nashville Predators to electrify Bridgestone Arena. This ain't just a handshake deal; it's a calculated step to transform how...

Concrete Admixtures Market: A Billion-Dollar Boom

A Look Under the Hood of Concrete Admixtures It's a concrete jungle out there, folks—literally. The once overlooked market of concrete admixtures is gearing up for quite the makeover, projected to hit USD 35.87 billion by 2035. For those of you tuning in, we're talking about chemicals that mix into your average concrete to change its properties. And, believe it or not,...